Those taking levothyroxine may require thyroid function monitoring, as semaglutide may increase levothyroxine exposure
The most significant safety concern is an FDA boxed warning for a potential risk of medullary thyroid carcinoma (MTC)
The agency said the crackdown intends to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy. The Department of Health and Human Services general counsel Mike Stuart, tweeted that the agency had reviewed the matter and referred Hims & Hers to the Department of Justice for investigation for potential violations of the Federal Food, Drug, and Cosmetic Act
Some patients also report reflux or feeling overly full, especially during dose changes
It is important to recognize that the impact of AOMs will vary by age, reflecting differences in obesity levels, the mortality risk associated with obesity, and differences in uptake
We have a lot more information toward the first question, and theres almost nothing toward the second question